Second Sight Medical Products, Inc.
Second Sight Medical Products, Inc. Fundamental Analysis
Second Sight Medical Products, Inc. (EYES) shows moderate financial fundamentals with a PE ratio of -6.70, profit margin of 141.87%, and ROE of -4.16%. The company generates $-0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -498.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze EYES's fundamental strength across five key dimensions:
Efficiency Score
WeakEYES struggles to generate sufficient returns from assets.
Valuation Score
ExcellentEYES trades at attractive valuation levels.
Growth Score
WeakEYES faces weak or negative growth trends.
Financial Health Score
WeakEYES carries high financial risk with limited liquidity.
Profitability Score
WeakEYES struggles to sustain strong margins.
Key Financial Metrics
Is EYES Expensive or Cheap?
P/E Ratio
EYES trades at -6.70 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, EYES's PEG of 0.09 indicates potential undervaluation.
Price to Book
The market values Second Sight Medical Products, Inc. at 188.85 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -5.18 times EBITDA. This is generally considered low.
How Well Does EYES Make Money?
Net Profit Margin
For every $100 in sales, Second Sight Medical Products, Inc. keeps $141.87 as profit after all expenses.
Operating Margin
Core operations generate 149.44 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-4.16 in profit for every $100 of shareholder equity.
ROA
Second Sight Medical Products, Inc. generates $-1.47 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Second Sight Medical Products, Inc. generates strong operating cash flow of $-26.14M, reflecting robust business health.
Free Cash Flow
Second Sight Medical Products, Inc. generates strong free cash flow of $-27.35M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $-0.54 in free cash annually.
FCF Yield
EYES converts -15.32% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-6.70
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.09
vs 25 benchmark
P/B Ratio
Price to book value ratio
188.85
vs 25 benchmark
P/S Ratio
Price to sales ratio
-807.87
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
13.97
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.61
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-4.16
vs 25 benchmark
ROA
Return on assets percentage
-1.47
vs 25 benchmark
ROCE
Return on capital employed
-2.13
vs 25 benchmark
How EYES Stacks Against Its Sector Peers
| Metric | EYES Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -6.70 | 29.28 | Better (Cheaper) |
| ROE | -416.18% | 820.00% | Weak |
| Net Margin | 14187.31% | -19743.00% (disorted) | Strong |
| Debt/Equity | 13.97 | 0.26 | Weak (High Leverage) |
| Current Ratio | 0.61 | 4.69 | Weak Liquidity |
| ROA | -147.28% | -17807.00% (disorted) | Weak |
EYES outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Second Sight Medical Products, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation